Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Epaminurad and Naproxen in Healthy Volunteers
NCT06435442Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of epaminurad in gout (3 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area under the plasma concentration versus time curve at 7 days and Peak plasma concentrations at 7 days. Started Jun 2024; status: completed.
02
Drugs
epaminurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT06435442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435442.